Multiple Myeloma Symptomatic | Measurable Disease
Item
symptomatic mm, based on imwg guidelines. patients must have measurable disease as defined by at least one of the following:
boolean
C0026764 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2])
M Protein | Serum protein electrophoresis | IgA myeloma | Immunoglobulin A measurement Quantitative
Item
1. serum m-protein ≥ 0.5 g/dl by serum electrophoresis (spep) or for iga myeloma, by quantitative iga; or
boolean
C0700271 (UMLS CUI [1])
C0201720 (UMLS CUI [2])
C0563305 (UMLS CUI [3])
C0202083 (UMLS CUI [4,1])
C0392762 (UMLS CUI [4,2])
Excretion measurement M Protein In Urine
Item
2. urinary m-protein excretion at least 200 mg/24 hours; or
boolean
C0201808 (UMLS CUI [1,1])
C0700271 (UMLS CUI [1,2])
C0042037 (UMLS CUI [1,3])
Serum Free Immunoglobulin Light Chain | Serum Immunoglobulin Free Light Chain Ratio Abnormal
Item
3. serum free light chain (flc) whereby the involved light chain measures ≥ 10 mg/dl and with an abnormal light chain ratio.
boolean
C2827352 (UMLS CUI [1])
C2826181 (UMLS CUI [2])
Therapeutic regimen Multiple Myeloma | Alkylating Agents | lenalidomide | pomalidomide | bortezomib | carfilzomib | Glucocorticoids
Item
patients must have received ≥ 3 prior anti-mm regimens including the following: an alkylating agent, lenalidomide, pomalidomide, bortezomib, carfilzomib and a glucocorticoid. there is no upper limit on the number of prior therapies provided that all other inclusion/exclusion criteria are met.
boolean
C1276413 (UMLS CUI [1,1])
C0026764 (UMLS CUI [1,2])
C0002073 (UMLS CUI [2])
C1144149 (UMLS CUI [3])
C2347624 (UMLS CUI [4])
C1176309 (UMLS CUI [5])
C2001856 (UMLS CUI [6])
C0017710 (UMLS CUI [7])
Multiple Myeloma Unresponsive to Treatment lenalidomide pomalidomide bortezomib carfilzomib | Disease Progression
Item
quad-refractory mm: mm refractory to lenalidomide, pomalidomide, bortezomib, and carfilzomib. refractory is defined as ≤ 25% response to therapy, or progression during therapy or progression within 60 days after completion of therapy.
boolean
C0026764 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C1144149 (UMLS CUI [1,3])
C2347624 (UMLS CUI [1,4])
C1176309 (UMLS CUI [1,5])
C2001856 (UMLS CUI [1,6])
C0242656 (UMLS CUI [2])
Multiple Myeloma Unresponsive to Treatment lenalidomide pomalidomide bortezomib carfilzomib daratumumab
Item
penta-refractory mm: 25% of patients must have mm refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and at least one anti-cd38 mab (e.g., sar 650984 or daratumumab)
boolean
C0026764 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C1144149 (UMLS CUI [1,3])
C2347624 (UMLS CUI [1,4])
C1176309 (UMLS CUI [1,5])
C2001856 (UMLS CUI [1,6])
C2346801 (UMLS CUI [1,7])
Multiple Myeloma Unresponsive to Treatment Most Recent
Item
multiple myeloma refractory to the patient's most recent anti-mm regimen.
boolean
C0026764 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C1513491 (UMLS CUI [1,3])
Smoldering myeloma
Item
smoldering mm.
boolean
C1531608 (UMLS CUI [1])
Leukemia, Plasma Cell
Item
plasma cell leukemia.
boolean
C0023484 (UMLS CUI [1])
Multiple Myeloma | Gene Expression | M Protein | Serum Free Immunoglobulin Light Chain | Non-secretory myeloma | Plasmacytoma
Item
mm that does not express m-protein or flc (i.e., non-secretory mm is excluded; plasmacytomas without m-protein or flc are excluded).
boolean
C0026764 (UMLS CUI [1])
C0017262 (UMLS CUI [2])
C0700271 (UMLS CUI [3])
C2827352 (UMLS CUI [4])
C0456845 (UMLS CUI [5])
C0032131 (UMLS CUI [6])
Primary amyloidosis of light chain type | Systemic amyloidosis | Amyloid
Item
documented systemic amyloid light chain amyloidosis.
boolean
C0342606 (UMLS CUI [1])
C0268380 (UMLS CUI [2])
C0002716 (UMLS CUI [3])
Central Nervous System Involvement with Multiple Myeloma
Item
active cns mm.
boolean
C3714787 (UMLS CUI [1,1])
C1314939 (UMLS CUI [1,2])
C0026764 (UMLS CUI [1,3])